Venatorx Pharmaceuticals
Venatorx Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary beta-lactam/beta-lactamase inhibitor antibiotic combinations to treat multi-drug-resistant bacterial infections, with a lead NDA-stage program (cefepime-taniborbactam) for complicated urinary tract infections and a Phase 3-ready asset (ceftibuten-ledaborbactam) out-licensed to Basilea.
- Company typePrivate
- Founded2010
- HeadquartersMalvern, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Venatorx Pharmaceuticals does
Venatorx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel anti-infective therapies for multi-drug-resistant bacterial infections, headquartered in Malvern, Pennsylvania. The company's pipeline is built around proprietary beta-lactam/beta-lactamase inhibitor combinations designed to overcome resistance mechanisms in Gram-negative pathogens. Its two lead assets are cefepime-taniborbactam, a combination antibiotic for which a New Drug Application has been filed for complicated urinary tract infections, and ceftibuten-ledaborbactam, a Phase 3-ready combination that has been out-licensed to Basilea Pharmaceutica for further development and commercialization. These programs target the global antimicrobial resistance crisis, serving an end market of hospitals, infectious-disease specialists, and health systems treating drug-resistant infections.
The company is privately held and venture-backed, founded in 2010 and operating with 51-100 employees. Capital has been raised through a mix of dilutive venture rounds — most recently a Series C Preferred Stock financing in April 2022 led by the AMR Action Fund with participation from Abingworth and other existing investors, and a subsequent ~$24.7 million exempt securities offering — and substantial non-dilutive funding from government and mission-driven sources including the National Institutes of Health, NIAID, the Defense Threat Reduction Agency, the Wellcome Trust, CARB-X, and SBIR. The business model is a hybrid of internal development through regulatory approval (for the lead asset) and partnership-based commercialization via out-licensing (for the second asset), rather than building a commercial sales organization. Scientific leadership rests with founders Luigi Xerri, PhD and Christopher J. Burns, PhD, with operating execution led by COO Ezra Felker and CBO Tony Meehan, PhD, and board oversight by Executive Chairman Manos Perros.
Venatorx Pharmaceuticals firmographics
Firmographics- Name
- Venatorx Pharmaceuticals
- Legal name
- Venatorx Pharmaceuticals, Inc.
- Website
- https://venatorx.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Venatorx Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary beta-lactam/beta-lactamase inhibitor antibiotic combinations to treat multi-drug-resistant bacterial infections, with a lead NDA-stage program (cefepime-taniborbactam) for complicated urinary tract infections and a Phase 3-ready asset (ceftibuten-ledaborbactam) out-licensed to Basilea.
- Ownership category
- akta.pro rank
Venatorx Pharmaceuticals industry classification
Industry- Product category
- Anti-infective Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Venatorx Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Markets served
Venatorx Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Venatorx Pharmaceuticals product offering
Product offeringCore offering
Venatorx Pharmaceuticals is a clinical-stage pharmaceutical company that discovers and develops novel anti-infective therapies to treat multi-drug-resistant bacterial and viral infections. Its lead product is cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections, with a New Drug Application filed. Its second key asset, ceftibuten-ledaborbactam, is a Phase 3-ready combination antibiotic out-licensed to Basilea Pharmaceutica.
Product overview
Venatorx Pharmaceuticals is a pharmaceutical company focused on developing novel antibiotics targeting drug-resistant bacteria. The company's antibacterial portfolio centers on two key drug candidates: cefepime-taniborbactam (which completed a new drug application submission for urinary tract infections) and ceftibuten-ledaborbactam (a Phase 3-ready asset that was in-licensed to Basilea Pharmaceutica). These products represent a pipeline of treatments addressing the global health crisis caused by antimicrobial resistance.
Differentiator
Problem solved
Functional benefit
Products and services
- Cefepime-taniborbactam A beta-lactam/beta-lactamase inhibitor combination antibiotic being developed for the treatment of complicated urinary tract infections caused by drug-resistant bacteria. Targeted at hospitals, infectious disease specialists, and healthcare systems treating patients with limited therapeutic options.
- Ceftibuten-Ledaborbactam A Phase 3-ready beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections, out-licensed to Basilea Pharmaceutica for further development and commercialization.
Quantifiable outcome
- New drug application filed for cefepime-taniborbactam for urinary tract infections
Companies that use Venatorx Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles2 records
Venatorx Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Venatorx Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Basilea Pharmaceutica AGcoreBasilea Pharmaceutica in-licensed the Phase 3-ready antibiotic Ceftibuten-Ledaborbactam from Venatorx Pharmaceuticals. This represents a strategic licensing partnership where Venatorx out-licenses its antibiotic candidate to Basilea for further development and commercialization.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Venatorx Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Basilea Pharmaceutica AG: Swiss-listed specialty anti-infectives company focused on antibiotics and antifungals. Direct comparable to Venatorx — Basilea in-licensed ceftibuten-ledaborbactam from Venatorx, and both companies target drug-resistant bacterial infections with hospital-channel products.
- Iterum Therapeutics: Clinical-stage anti-infectives company developing oral and IV antibiotics for drug-resistant infections, including complicated UTIs. Comparable to Venatorx as a small-cap, antibiotic-focused developer pursuing the same indication space.
- Melinta Therapeutics: Specialty antibiotics company with marketed products for drug-resistant infections (including UTIs). Comparable as a focused anti-infectives commercial/specialty pharma serving hospital channels.
- Entasis Therapeutics: Anti-infectives company (acquired by Innoviva) developing targeted antibiotics for serious drug-resistant infections. Comparable to Venatorx as a small, science-driven developer of novel antibiotic combinations addressing AMR.
- Paratek Pharmaceuticals: Commercial-stage specialty pharma with antibiotic products targeting serious community- and hospital-acquired infections. Comparable to Venatorx as a focused anti-infectives developer/commercializer serving similar hospital channels.
- Nabriva Therapeutics: Biopharmaceutical company developing antibiotics for serious infections including complicated UTIs. Comparable to Venatorx as a small-cap clinical/commercial-stage antibiotic developer in overlapping indications.
Emerging players
- Cidara Therapeutics: Clinical-stage anti-infectives company developing antivirals and antifungal conjugates. Comparable as a small-cap developer addressing drug-resistant infectious diseases, though Cidara's lead assets are antiviral/antifungal rather than antibacterial.
Broad incumbents
- Shionogi & Co., Ltd. Japanese multinational with a strong antibiotics franchise including cefiderocol (an antibacterial for resistant Gram-negative infections). Comparable as an established player with overlapping antibacterial R&D and commercialization capability.
- GSK plc: Global pharma with a meaningful anti-infectives portfolio including gepotidacin (a late-stage antibiotic for UTIs and gonorrhea). Comparable as a broad incumbent competing with Venatorx in the cUTI space with greater commercial reach.
- Pfizer Inc. Global pharmaceutical incumbent with an established antibiotics franchise (e.g., Zavicefta) and broad hospital-channel reach. Comparable as a broad incumbent in the antibacterial space that Venatorx's hospital-targeted products would compete against.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Venatorx Pharmaceuticals social profiles
Digital presenceVenatorx Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Venatorx Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
Venatorx Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds13 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Venatorx Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Venatorx Pharmaceuticals
What does Venatorx Pharmaceuticals do?
Venatorx Pharmaceuticals is a clinical-stage pharmaceutical company that discovers and develops novel anti-infective therapies to treat multi-drug-resistant bacterial and viral infections. Its lead product is cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections, with a New Drug Application filed. Its second key asset, ceftibuten-ledaborbactam, is a Phase 3-ready combination antibiotic out-licensed to Basilea Pharmaceutica.
Is Venatorx Pharmaceuticals a public or private company?
Venatorx Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Venatorx Pharmaceuticals founded?
Venatorx Pharmaceuticals was founded in 2010. It employs 51 to 100 people.
Where is Venatorx Pharmaceuticals based?
Venatorx Pharmaceuticals is headquartered in Malvern, United States, in the North America region.
Who are Venatorx Pharmaceuticals's main competitors?
Direct peers on record are Basilea Pharmaceutica AG, Iterum Therapeutics, Melinta Therapeutics, Entasis Therapeutics, Paratek Pharmaceuticals and Nabriva Therapeutics. Cidara Therapeutics is listed as an emerging player. Broad incumbents are Shionogi & Co., Ltd., GSK plc and Pfizer Inc..
Does Venatorx Pharmaceuticals have an API?
No public API is recorded for Venatorx Pharmaceuticals.
What industry is Venatorx Pharmaceuticals in?
Venatorx Pharmaceuticals's product category is Anti-infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 3841.